60
Participants
Start Date
August 1, 2025
Primary Completion Date
August 1, 2026
Study Completion Date
November 1, 2026
Control (Standard treatment)
Patients in the control arm will be treated with a standard zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
Novel Barrier Cream
Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
The Salvation Army Toronto Grace Health Centre
UNKNOWN
Scotiaderm
OTHER